Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines

Journal of Clinical Oncology

Volumn 24, Issue 16, 2006, Pages 2444-2447

  Smith, Ian E ^a   Dowsett, Mitch ^a   Yap, Yoon Sim ^a   Walsh, Geraldine ^a   Lønning, Per E ^a   Santen, Richard J ^a   Hayes, Daniel ^a  

^a MI

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; ESTRADIOL; EXEMESTANE; FOLLITROPIN; LETROZOLE; LUTEINIZING HORMONE; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; DISEASE DURATION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUATION; OVARY FUNCTION; PREGNANCY; PRIORITY JOURNAL; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST TUMOR; CANCER STAGING; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; OVARIECTOMY; PATHOLOGY; PRACTICE GUIDELINE;

ADULT; AMENORRHEA; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR MODULATORS; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; NEOPLASM STAGING; NITRILES; OVARIECTOMY; PRACTICE GUIDELINES; TAMOXIFEN; TRIAZOLES;

EID: 33745005540     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.3694     Document Type: Article

References (15)

1. ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
2. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
3. BIG 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
4. Jakesz R, Samonigg H, Greil R, et al: Extended adjuvant treatment with anastrozole: Results from the ABCSG 6a Trial. J Clin Oncol 23:10s, 2005 (suppl; abstr 527)
5. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005
6. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729, 1996
7. Goodwin PJ, Ennis M, Pritchard KI, et al: Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17:2365-2370, 1999
8. Bianco AR, Del Mastro L, Gallo C, et al: Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 63:799-803, 1991
9. Mitwally MF, Casper RF: Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75:305-309, 2001
10. Fisher SA, Reid RL, Van Vugt DA, et al: A randomized double-blind comparison of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 78:280-285, 2002
11. Dowsett M, Richner J: Effects of cytotoxic chemotherapy on ovarian and adrenal steroidogenesis in pre-menopausal breast cancer patients. Oncology 48:215-220, 1991
12. Singh KL, Davies M, Chatterjee R: Fertility in female cancer survivors: Pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 11:69-89, 2005
13. Dowsett M, Folkerd E: Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 7:1-4, 2005
14. Johannessen DC, Engan T, DiSalle E, et al: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 3:1101-1108, 1997
15. Krop IE, Winer EP: Ovarian suppression for breast cancer: An effective treatment in search of a home. J Clin Oncol 23:5869-5872, 2005